Form 4: Opus Genetics Director Acquires Shares in Lieu of Cash Compensation

Opus Genetics director, Jean Bennett, acquired 34,021 shares of common stock on January 2, 2025, as compensation for board services.

Summary

• Jean Bennett, a director at Opus Genetics, acquired 34,021 shares of common stock on January 2, 2025.
• These shares were granted in lieu of cash compensation for board services for the year 2025.
• The number of shares was calculated by dividing the total retainer amount for board services by the average fair market value of a share on the grant date.
• The average fair market value of the stock on the grant date was $1.23 per share.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock compensation for a director, which is generally viewed neutrally to slightly positive as it aligns interests. There are no negative implications.

Positives

• The acquisition of shares by a director demonstrates alignment of interests with shareholders.
• The use of stock as compensation can conserve cash resources for the company.

Industry Context

This type of stock-based compensation is common practice for board members in publicly traded companies, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock-based compensation for board members is a common practice across the biotechnology industry.
• Many companies, such as Amgen and Regeneron, use a mix of cash and stock options to compensate their directors.
• The specific amount and valuation of the stock grant are typical for a company of Opus Genetics' size and stage.

Stakeholder Impact

• Shareholders may view this as a positive sign of director commitment.
• The use of stock instead of cash may be seen as beneficial for the company's financial position.

Key Dates

Keywords

Opus Genetics, director, share acquisition, stock compensation, board services, Form 4, insider trading